Passa al contenuto
Merck

Selective inhibition of glycosyltransferases by bivalent imidazolium salts.

Bioorganic & medicinal chemistry (2013-02-05)
Yin Gao, Jason Z Vlahakis, Walter A Szarek, Inka Brockhausen
ABSTRACT

Galactosyltransferases (GalTs) extend the glycan chains of mammalian glycoproteins by adding Gal to terminal GlcNAc residues, and thus build the scaffolds for biologically important glycan structures. We have shown that positively charged bivalent imidazolium salts in which the two imidazolium groups are linked by an aliphatic chain of 20 or 22 carbons form potent inhibitors of purified human β3-GalT5, using GlcNAcβ-benzyl as acceptor substrate. The inhibitors are not substrate analogs and also inhibited a selected number of other glycosyltransferases. These bis-imidazolium compounds represent a new class of glycosyltransferase inhibitors with potential as anti-cancer and anti-inflammatory drugs.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Imidazolo, ReagentPlus®, 99%
Sigma-Aldrich
Imidazolo, for molecular biology, ≥99% (titration)
Sigma-Aldrich
Imidazole buffer Solution, BioUltra, 1 M in H2O
Sigma-Aldrich
Imidazolo, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
Imidazole hydrochloride
Sigma-Aldrich
Imidazolo, ACS reagent, ≥99% (titration)
Sigma-Aldrich
Imidazolo, ≥99% (titration), crystalline
Sigma-Aldrich
Imidazolo, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
Imidazolo, puriss. p.a., ≥99.5% (GC)
Sigma-Aldrich
Imidazole sodium derivative, technical grade
Supelco
Imidazolo, Pharmaceutical Secondary Standard; Certified Reference Material
Imidazolo, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Imidazolo, ReagentPlus®, 99%, Redi-Dri, free-flowing
Sigma-Aldrich
Imidazolo, for molecular biology, ≥99% (titration), free-flowing, Redi-Dri